Treatment and Prevention of Bone Loss Using Resolvins

• US 20080280980A1
• Filed: 11/17/2006
• Published: 11/13/2008
• Est. Priority Date: 11/18/2005
• Status: Active Grant

• Current Assignee: Forsyth Dental Infirmary For Children
• Original Assignee: Trustees of Boston University
• Inventors: Van Dyke, Thomas E.
• Granted Patent: US 8,636,986 B2
• Time in Patent Office: Days
• US Class Current: 514/560
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/202 having three or more double bonds, e.g. linolenic eicosanoids, e.g. leukotrienes A61K31/557
• CPC Class Codes: A61K 31/22 of acyclic acids, e.g. pravastatin
• CPC Class Codes: A61K 31/557 Eicosanoids, e.g. leukotrienes or prostaglandins
• CPC Class Codes: A61K 31/663 Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 19/08 for bone diseases, e.g. rachitism, Paget's disease
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present invention provides new methods for inducing or promoting bone growth and/or for reducing or preventing bone deterioration in a mammal subject. The inventive methods generally comprise administering to the subject an effective amount of a resolvin. In particular, the inventive methods may be useful for treating or preventing conditions associated with bone degradation, deterioration or degeneration such as periodontal disease, osteoarthritis, and metastatic bone disease and osteolytic bone disease. Pharmaceutical compositions and kits comprising at least one resolvin are also provided that can be used to performed the inventive methods.

Claims

1. A method of promoting bone growth in a vertebrate subject suffering from a bone condition, the method comprising a step of administering to the subject an effective amount of at least one resolvin.

3. The method of claim 1, wherein the method results in an increase of bone mass, an increase of bone density, or a combination thereof.

4. The method of claim 1, wherein the vertebrate subject is a human patient.

5. The method of claim 1, wherein said at least one resolvin is administered topically.

6. The method of claim 5, wherein said at least one resolvin is administered topically to the subject'"'"'s oral cavity.

7. The method of claim 1, wherein said at least one resolvin is administered enterally.

8. The method of claim 7, wherein said at least one resolvin is administered orally.

9. The method of claim 1, wherein said at least one resolvin is selected from the group consisting of members of the Resolvin E series, members of the Resolvin D series, and combinations thereof.

10. The method of claim 9, wherein said at least one resolvin is selected from the group consisting of di-hydroxy members of the Resolvin E series, di-hydroxy members of the Resolvin D series, tri-hydroxy members of the Resolvin E series, tri-hydroxy members of the Resolvin D series, and combinations thereof.

11. The method of claim 1, wherein said at least one resolvin comprises Resolvin E1.

12. The method of claim 1, wherein said method further comprises a step of administering to the subject an effective amount of a therapeutic agent that promotes bone growth or inhibits bone resorption.

13. The method of claim 12, wherein the step of administering said resolvin and the step of administering said therapeutic agent that promotes bone growth or inhibits bone resorption are performed sequentially.

14. The method of claim 12, wherein the step of administering said resolvin and the step of administering said therapeutic agent that promotes bone growth or inhibits bone resorption are performed simultaneously.

15. The method of claim 12, wherein said therapeutic agent that promotes bone growth or inhibits bone resorption is selected from the group consisting of bone morphogenetic factors, anti-resorptive agents, osteogenic factors, cartilage-derived morphogenetic proteins, growth hormones, estrogens, bisphosphonates, statins, differentiating factors, and combinations thereof.

16. The method of claim 1, wherein said bone condition is selected from the group consisting of periodontal disease, bone fracture, bone deficiency, metastatic bone disease, osteoarthritis, and osteolytic bone disease.

17. The method of claim 16, wherein said subject is suffering from gingivitis or periodontitis.

2. (canceled)

18-46. -46. (canceled)